Fengdi Li
Impact in
- Infectious Diseases top 0.5%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- Epidemiology top 5%
- Influenza Virus Research Studies
Papers in
- Epidemiology 27
- Influenza Virus Research Studies 23
- Hepatitis B Virus Studies 4
-
- SARS-CoV-2 and COVID-19 Research 18
- COVID-19 Clinical Research Studies 6
- Co-authors
- Linlin Bao (37 shared papers)Chuan Qin (26 shared papers)Wei Deng (20 shared papers)Qi Lv (34 shared papers)Pin Yü (14 shared papers)Yanfeng Yao (10 shared papers)Hong Gao (3 shared papers)Honglin Chen (6 shared papers)
In The Last Decade
Fengdi Li
61 papers receiving 3.9k citations
Fengdi Li's Hit Papers
Peers
Comparison fields: 5 of 127
- Infectious Diseases 2.5k
- Epidemiology 469
- Drug Discovery 4
- Immunology 268
- Complementary and alternative medicine 109
Countries citing papers authored by Fengdi Li
This map shows the geographic impact of Fengdi Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengdi Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengdi Li more than expected).
Fields of papers citing papers by Fengdi Li
This network shows the impact of papers produced by Fengdi Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengdi Li. The network helps show where Fengdi Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Fengdi Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 66 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice Hit paper breakdown → | 2020 | 934 |
| 2 | 2020 | 624 | |
| 3 | Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset Hit paper breakdown → | 2015 | 525 |
| 4 | 2020 | 363 | |
| 5 | 2020 | 227 | |
| 6 | 2020 | 140 | |
| 7 | Bioactive compounds from Huashi Baidu decoction possess both antiviral and anti-inflammatory effects against COVID-19 Hit paper breakdown → | 2023 | 102 |
| 8 | 2018 | 74 | |
| 9 | 2013 | 73 | |
| 10 | 2021 | 66 | |
| 11 | 2021 | 65 | |
| 12 | 2017 | 63 | |
| 13 | 2019 | 48 | |
| 14 | 2014 | 45 | |
| 15 | 2020 | 44 | |
| 16 | 2013 | 34 | |
| 17 | 2018 | 31 | |
| 18 | 2011 | 30 | |
| 19 | 2010 | 28 | |
| 20 | 2011 | 26 |
About Fengdi Li
Fengdi Li is a scholar working on Epidemiology, Infectious Diseases, Immunology, Polymers and Plastics and Cardiology and Cardiovascular Medicine, having authored 66 papers that have together received 4k indexed citations. Recurring topics across this work include Influenza Virus Research Studies (23 papers), SARS-CoV-2 and COVID-19 Research (18 papers), COVID-19 Clinical Research Studies (6 papers), Hepatitis B Virus Studies (4 papers), Viral Infections and Immunology Research (4 papers), Polymer composites and self-healing (3 papers), Advanced Battery Materials and Technologies (3 papers) and IL-33, ST2, and ILC Pathways (3 papers). The work is most often cited by research in Infectious Diseases (2.5k citations), Epidemiology (469 citations), Drug Discovery (4 citations), Immunology (268 citations) and Complementary and alternative medicine (109 citations). Fengdi Li has collaborated with scholars based in China, Hong Kong and Australia. Frequent co-authors include Linlin Bao, Chuan Qin, Wei Deng, Qi Lv, Pin Yü, Yanfeng Yao, Hong Gao, Honglin Chen, Yanfeng Xu and Kwok‐Yung Yuen. Their work appears in journals such as Signal Transduction and Targeted Therapy, Virology Journal, Viruses, The Journal of Infectious Diseases and Virus Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.